$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/14
  • A61K-009/16
출원번호 UP-0887204 (2001-06-22)
등록번호 US-7674480 (2010-04-21)
발명자 / 주소
  • Fleshner-Barak, Moshe
  • Lerner, E. Itzhak
  • Rosenberger, Vered
  • Dahan, Mazal
  • Makov, Yisrael
출원인 / 주소
  • Teva Pharmaceutical Industries Ltd.
대리인 / 주소
    Kenyon & Kenyon LLP
인용정보 피인용 횟수 : 1  인용 특허 : 59

초록

The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention

대표청구항

What is claimed is: 1. A pharmaceutical dosage form for oral administration to a patient providing pulsed gastric release of methylphenidate comprising: a) a gastric retention vehicle composition comprising about 10 wt-% to about 75 wt-% superdisintegrant, about 2 wt-% to about 12 wt-% tannic acid,

이 특허에 인용된 특허 (59)

  1. Shih, Chung; Zentner, Gaylen, Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles.
  2. Joaquina Faour AR, Combined diffusion/osmotic pumping drug delivery system.
  3. Moshe Flashner-Barak IL; Vered Rosenberger IL; Mazal Dahan IL; Yitzhak Lerner IL, Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates.
  4. Juan Mantelle ; Terese A. Dixon, Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate.
  5. Mantelle Juan ; Dixon Terese A., Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate.
  6. Padmanabh Bhatt ; Evangeline Cruz ; Noymi Yam, Controlled delivery of active agents.
  7. Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
  8. Drost Joseph D. (Monmouth Junction NJ) Reier George E. (Somerset NJ) Jain Nemichand B. (Monmouth Junction NJ), Controlled release formulation.
  9. Thinnayam N. Krishnamurthy CA; Andrew Darke CA, Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations.
  10. Mehta Atul M. (252 E. Crescent Ave. Ramsey NJ 07446), Controlled release indomethacin.
  11. Patrick S. -L. Wong ; David E. Edgren ; Liang C. Dong ; Crystal Pollock-Dove, Controlled release liquid active agent formulation dosage forms.
  12. Zatz Joel L. (Metuchen NJ) Woodford David W. (Rensselaer NY), Controlled release liquid pharmaceutical.
  13. Goldenheim, Paul D.; Sackler, Richard S.; Krishnamurthy, Thinnayam N.; Darke, Andrew; Oshlack, Benjamin, Controlled/modified release oral methylphenidate formulations.
  14. Goldenheim,Paul D.; Sackler,Richard S.; Krishnamurthy,Thinnayam N.; Darke,Andrew; Oshlaci,Benjamin, Controlled/modified release oral methylphenidate formulations.
  15. Cartilier Louis,CAX ITX H9W 2M7 ; Chebli Chafic,CAX ITX H9G 2V5, Cross-linked cellulose as a tablet excipient.
  16. Mehta Atul M. ; Zeitlin Andrew L. ; Dariani Maghsoud M., Delivery of multiple doses of medications.
  17. Mehta, Atul M.; Zeitlin, Andrew L.; Dariani, Maghsoud M., Delivery of multiple doses of medications.
  18. Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
  19. Caldwell Larry J. (Lawrence KS) Gardner Colin R. (Lawrence KS) Cargill Robyn C. (Lawrence KS), Drug delivery device which can be retained in the stomach for a controlled period of time.
  20. Caldwell Larry J. (Lawrence KS) Gardner Colin R. (Lawrence KS) Cargill Robyn C. (Lawrence KS) Higuchi Takeru (Lawrence KS), Drug delivery device which can be retained in the stomach for a controlled period of time.
  21. Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Drug delivery system comprising a reservoir containing a plurality of tiny pills.
  22. Urquhart John (Palo Alto CA) Theeuews Felix (Los Altos CA), Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills.
  23. Gehrke Stevin H. (Cincinnati OH) Lupton E. C. (Boston MA) Schiller Matthew E. (Waltham MA) Uhden Lorelle (Cincinnati OH) Vaid Nitin (Kanpur INX), Enhanced loading of solutes into polymer gels.
  24. John W. Shell ; Jenny Louie-Helm ; Micheline Markey, Extending the duration of drug release within the stomach during the fed mode.
  25. Curatolo William J. (Niantic CT) Lo Jeelin (Old Lyme CT), Gastric retention system for controlled drug release.
  26. Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
  27. Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills.
  28. Illum Lisbeth,GBX ; Ping He, Gastroretentive controlled release microspheres for improved drug delivery.
  29. Park Kinam ; Chen Jun ; Park Haesun, Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties.
  30. Viegas Tacey X. ; Reeve Lorraine E. ; Henry Raymond L., Medical uses of in situ formed gels.
  31. Lindahl, Ake R.; Erlandsson, Stig A. B., Membrane-coated sustained-release tablets and method.
  32. Fahn Stanley (155 Edgars La. Hastings-on-Hudson NY 10706), Method and compositions of treating Parkinsonisms with levodopa and 3′,4′-dihydroxy-2-methylisopropiophenone.
  33. Theeuwes Felix (Los Altos CA), Method for adminstering tiny pills.
  34. Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Hatamkhany, Zahedeh; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Weyers, Richar, Methods and devices for providing prolonged drug therapy.
  35. Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
  36. Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
  37. Marie J. Bettman ; Phillip J. Percel ; Dan L. Hensley ; Krishna S. Vishnupad ; Gopi M. Venkatesh, Methylphenidate modified release formulations.
  38. Sheth Prabhakar R. (Pearl River NY) Tossounian Jacques L. (Pine Brook NJ), Novel sustained release tablet formulations.
  39. Mockel Jorn,DEX ; Gabel Rolf-Dieter,DEX ; Woog Heinrich,DEX, Oral pharmaceutical preparation containing ibandronat.
  40. Burnside Beth A. ; Guo Xiaodi ; Fiske Kimberly ; Couch Richard A. ; Treacy Donald J. ; Chang Rong-Kun ; McGuinness Charlotte ; Rudnic Edward M., Oral pulsed dose drug delivery system.
  41. Talwar Naresh,INX ; Sen Himadri,INX ; Staniforth John N.,GBX, Orally administered controlled drug delivery system providing temporal and spatial control.
  42. Swanson David (Palo Alto CA) Edgren David (El Granada CA), Osmotic device that improves delivery properties of agent in situ.
  43. Cohen Sasson,ILX ; Yoram Sela,ILX ; Levy Ruth,ILX ; Shterman Nava,ILX ; Melamed Eldad,ILX ; Atlas Dafna,ILX, Pharmaceutical composition of L-DOPA ester.
  44. Kamal K. Midha BM; Theodore L. Iorio ; Shubha Chungi, Pharmaceutical dosage form for pulsatile delivery of methylphenidate.
  45. Conte Ubaldo,ITX ; Maggi Lauretta,ITX, Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids.
  46. Staibano Giorgio (Coltano ITX), Process for the preparation of diphosphonic acids.
  47. Panoz Donald (Tuckerstown BMX) Corneille Gilbert (Paris FRX), Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained the.
  48. Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
  49. Himmelstein Kenneth J. (Omaha NE) Baustian Cara L. (Pearl River NY 4), Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use.
  50. Wong Patrick S. L. (Palo Alto) Theeuwes Felix (Los Altos) Larsen Steven D. (Dublin CA), Self-retaining gastrointestinal delivery device.
  51. Miranda Jesus ; Sablotsky Steven, Solubility parameter based drug delivery system and method for altering drug saturation concentration.
  52. Alderman Daniel A. (Midland MI), Sustained release compositions comprising hydroxypropyl cellulose ethers.
  53. Gaylord Norman G. (New Providence NJ) Nigalaye Ashok (East Rockaway NY), Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates.
  54. Lovegrove Claire J. (Ware GB2) Rawlins David A. (Tewin GB2) Phillips Anthony J. (Little Hadham GB2) Tainsh David A. (Buntingford GB2), Sustained release pharmaceutical compositions in oral dosage form.
  55. Sheth Prabhakar R. (Pearl River NY) Tossounian Jacques L. (Pine Brook NJ), Sustained release tablet formulations.
  56. Franz Michel R. (Brussels BEX) Oth Marianne P. (Brussels BEX), Sustained release, bilayer buoyant dosage form.
  57. Baker Helen Frances,GBX ; Gilbert Julian Clive,GBX, Sustained-release formulation of methylphenidate.
  58. Shell John W. (Hillsborough CA), Sustained-release oral drug dosage form.
  59. Hammond Michael Douglas (Chesham EN) Schneider Cyril (Whitton EN), Treatment of ethanol withdrawal symptoms with levodopa.

이 특허를 인용한 특허 (1)

  1. Kim, In-Ae; Kim, Sang-Hee; Jung, Ji-Hoon; Chang, Hee-Chul; Maeng, Jin-Hee; Yang, Su-Geun; Lee, Don-Haeng; Min, Kyung-Hyun, Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트